Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: zoledronate therapy Clear all
Completed Phase 3 Interventional Results available

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

NCT00439244
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic acid, Placebo, Teriparatide
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 89 Years · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 1 Interventional

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

NCT02274623
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia, Hyperparathyroidism, Secondary
Interventions
CTAP101 Capsules
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Long Beach, California • Miami, Florida • Evergreen Park, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Not applicable Interventional Results available

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

NCT01205646
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronate therapy, PET Scan
Drug · Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 2 Interventional

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

NCT00151073
View directory record Official record
Conditions
Hormone-Refractory Prostate Cancer
Interventions
Zoledronic acid, Estramustine, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 2 Interventional Results available

Prevention of Bone Loss After Acute SCI by Zoledronic Acid

NCT02325414
View directory record Official record
Conditions
Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions
Zoledronic acid, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 10, 2026, 3:26 PM EDT
Terminated Not applicable Interventional Results available

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

NCT01409811
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 4 Interventional Results available

Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women

NCT00927186
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Teriparatide, Zoledronic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 89 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Lakewood, Colorado • Atlanta, Georgia • Gainesville, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 10, 2026, 3:26 PM EDT
Active, not recruiting Phase 2 Interventional

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

NCT03073785
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions
Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy, Zoledronic Acid
Drug · Other · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 10, 2026, 3:26 PM EDT
Not listed Phase 3 Interventional

CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1

NCT02504008
View directory record Official record
Conditions
Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
Interventions
AXS-02 (oral zoledronate), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
29
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 10, 2026, 3:26 PM EDT
Terminated Phase 3 Interventional Results available

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

NCT02516423
View directory record Official record
Conditions
Solitary Osseous Plasmacytoma
Interventions
ixazomib, lenalidomide, dexamethasone, zoledronic acid
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
388
States / cities
Anchorage, Alaska • Burbank, California • Clovis, California + 267 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Not applicable Interventional Results available

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NCT00436917
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid, Letrozole as adjuvant therapy
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Not applicable Interventional

A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy

NCT00087659
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
16
States / cities
Tucson, Arizona • Long Beach, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2009 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

NCT00558272
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bone Neoplasms
Interventions
AZD0530, Zoledronic Acid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Pleasant Hill, California • Sacramento, California • Middlebury, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

NCT00566618
View directory record Official record
Conditions
Breast Cancer, Bone Metastases
Interventions
Dasatinib, Zoledronic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 2 Interventional Results available

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

NCT00083382
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pamidronate, Thalidomide, Zometa
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 10, 2026, 3:26 PM EDT
Terminated Phase 3 Interventional

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

NCT00005073
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 10, 2026, 3:26 PM EDT
Not listed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions

NCT02746068
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
AXS-02, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
54
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 10, 2026, 3:26 PM EDT
Terminated Phase 2 Interventional Results available

Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer

NCT01004510
View directory record Official record
Conditions
Malignant Pleural Effusion, Non Small Cell Lung Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Peter Bushunow MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 4 Interventional

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

NCT00063609
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 10, 2026, 3:26 PM EDT
Recruiting No phase listed Observational

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

NCT03958565
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tyrosine Kinase Inhibitor, Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA], Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Biological · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

NCT01204203
View directory record Official record
Conditions
Mesothelioma
Interventions
Zometa
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 3 Interventional Results available

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

NCT00079001
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
zoledronic acid, placebo, androgen deprivation therapy, GnRH agonist, Calcium supplement, Vitamin D
Drug · Other · Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
238
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 159 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 10, 2026, 3:26 PM EDT
Completed No phase listed Observational

Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis

NCT00264082
View directory record Official record
Conditions
Breast Cancer
Interventions
Zometa(drug)
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 10, 2026, 3:26 PM EDT
Completed Phase 2 Interventional

Bisphosphonate Treatment of Osteogenesis Imperfecta

NCT00063479
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Zoledronic Acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 17 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Wilmington, Delaware • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 10, 2026, 3:26 PM EDT